Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
55M
-
Number of holders
-
117
-
Total 13F shares, excl. options
-
58.2M
-
Shares change
-
-3.32M
-
Total reported value, excl. options
-
$715M
-
Value change
-
-$45.8M
-
Put/Call ratio
-
5.24
-
Number of buys
-
57
-
Number of sells
-
-56
-
Price
-
$12.29
Significant Holders of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) as of Q3 2024
140 filings reported holding STOK - Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q3 2024.
Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) has 117 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 58.2M shares
.
Largest 10 shareholders include Skorpios Trust (8.91M shares), BlackRock, Inc. (5.57M shares), Lynx1 Capital Management LP (5.19M shares), Redmile Group, LLC (4.71M shares), RTW INVESTMENTS, LP (4.65M shares), BAKER BROS. ADVISORS LP (4.37M shares), MORGAN STANLEY (4.21M shares), COWEN AND COMPANY, LLC (3.24M shares), VANGUARD GROUP INC (2.76M shares), and STATE STREET CORP (1.73M shares).
This table shows the top 117 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.